Recent Updates
Recently added Catalysts

IN8bio, Inc.

INABFDA catalysts, PDUFA dates & pipeline intelligence
$0.82
▲ +0 · +0.49%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full INAB financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.7252W HIGH $2.73
Volume
121.16 K
Value Traded
102.30 K
Short % Float
0.16%
Days to Cover
1.0
-5.93%Week
-24.77%1 Month
-31.67%3 Month
-47.77%6 Month
-99.44%5 Year
-99.44%All Time

Cash Data

Unlock INAB cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
8.86 M
EPS (TTM)
-1.80
P/E Ratio
-
Ent. Value
-5.11 M
Total Shares
10.81 M
Float Shares
10.01 M
Insiders
7.35%
Institutions
34.99%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Pre-clinical data readout
INB-619
oncology and autoimmune diseases
Pre-clinicalBiologicsOncology
Unlock every INAB catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

INAB Catalyst Timeline

Dated clinical, regulatory and corporate events for IN8bio, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for IN8bio, Inc.

431Total events
9Upcoming
38Tier-1 (high impact)
2020 to 2027Coverage

Upcoming catalysts 2

T2Oral Presentation
Subscribe to view catalyst details
INB-100
T2IND Submission
Subscribe to view catalyst details
INB-619

Event history 50

▲Full ResultsINB-200Clinical Data
Final updated Phase 1/2 results for INB-200/INB-400 in newly diagnosed GBM presented at SNO 2026
newly diagnosed glioblastoma (GBM)source ↗
▲Long Term DataINB-400Clinical Data
Two-year survival and long-term follow-up data for repeat-dose gamma-delta T cell therapy in GBM
newly diagnosed glioblastoma (GBM)source ↗
▲Oral PresentationINB-200Presentation
Oral presentation of INB-200/INB-400 final Phase 1/2 results at SNO 2026 Annual Meeting
newly diagnosed glioblastoma (GBM)source ↗
●Quarterly UpdateCorporate
Reported third quarter 2026 financial results
▲Grant / FundingCorporate
Inducement stock option grant of 60,000 shares to one new employee
●Preclinical PoCINB-619Preclinical
INB-619 featured in Nature Reviews Drug Discovery review of next-generation immune cell engagers
oncology and autoimmune diseasessource ↗
●R&D DayPresentation
IN8bio presentation at Sidoti Small-Cap Virtual Conference
●R&D DayPresentation
IN8bio to present fireside chat at H.C. Wainwright 28th Annual Global Investment Conference
●Management ChangeCorporate
IN8bio appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
●Management ChangeCorporate
Oxana Polyakova, Ph.D. appointed Senior Vice President of Research & Development
Unlock the full INAB catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How INAB actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-02-12DeltEx Drug Resistant Immunotherapy (DRI) Phase 1/2 data readout Phase 1/2
Unlock 8 more INAB historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 82%
Micro Cap
(rank 595 of 725)
Percentile Rank
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
INB-400 BiologicsNCT05664243GlioblastomaPhase 1/2 ACTIVE NOT_RECRUITING 4Dec 1, 2026
Unlock the INAB pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every INAB program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
gamma-delta T cell therapy newly diagnosed glioblastomaPhase 1/22026-11-16median overall survival: 20.9 months; two year survival: 50%; median progression free survival: 13.0 months; standard of care median overall survival: 13.2 months; standard of care median progression free survival: 6.6 months; control group two year survival: 10%Read MoreIN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell TherapyRead More
Scroll for more · summaries link to the source press release
Unlock every INAB trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock INAB insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
FAIRBAIRN EMILYDirectorDisposition -724,637 $0.00 05/27/2026
Unlock the full INAB insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in INAB for Q3 2026.
Unlock every fund holding INAB
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in INAB
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see INAB ownership
Insider and institutional ownership, quarter by quarter.

INAB Short Interest

Shares sold short, counted twice a month.

0.16%
Short % of Float
of tradable shares sold short
15.7K
Shares Sold Short
-52.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
36.2K
Avg Daily Volume
the average used for days to cover
Unlock INAB short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock INAB option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live INAB option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock INAB options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How INAB ranks across every disease it competes in

Competitive Position is a premium feature
See how INAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

INAB News

INAB
Nov 16, 2026
INABPhases
▲ +0.5%today

IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy

IN8bio reported updated glioblastoma data at the SNO 2026 meeting, showing a median overall survival of 20.9 months for patients receiving repeat doses of gamma-delta T cell therapy. This is a 59% improvement over standard-of-care. Additionally, 50% of these patients survived for two years, compared to just 10% in the control group. The therapy also exhibited a favorable safety profile.

Read more →
INAB
Nov 6, 2026
INABGeneral

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio, Inc. announced the grant of a nonqualified stock option for 4,000 shares to a new employee. This award, approved by the Compensation Committee, is part of the 2026 Inducement Plan and complies with Nasdaq Listing Rule 5635(c)(4). The stock option will vest over four years, promoting employee retention.

Read more →
INAB
Nov 5, 2026
INABGeneral
▲ +11.6%on this newsshared move

IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights

IN8bio reported its third quarter 2026 financial results, highlighting the appointment of Dr. Oxana Polyakova as Senior VP of R&D. The company received recognition for INB-619 in a Nature Reviews article. They remain on track to present initial in vivo data for INB-619 by the end of 2026.

Read more →
INAB
Sep 22, 2026
INABConferences/Events

IN8bio to Present at Sidoti Small-Cap Virtual Conference

IN8bio, Inc. announced that CEO William Ho will present at the Sidoti Small-Cap Virtual Conference on September 24, 2026. The presentation will highlight the company's unique gamma-delta T cell platform and its lead program, INB-619, along with other clinical-stage initiatives. Investors can participate in one-on-one meetings during the event.

Read more →
INAB
Sep 10, 2026
INABConferences/Events

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

IN8bio, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. CEO William Ho will lead a fireside chat and the management team will meet with investors. The event will be webcasted for broader access.

Read more →
INAB
Sep 9, 2026
INABGeneral
▼ -5.3%on this newsshared move

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

IN8bio has appointed Dr. Oxana Polyakova as Senior Vice President of Research & Development. Dr. Polyakova, an expert in gamma-delta T cell biology, brings extensive experience from her previous roles in various biotech companies. Her leadership is expected to enhance IN8bio's T cell engager programs and advance their therapeutic pipeline.

Read more →
INAB
Aug 6, 2026
INABGeneral

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

IN8bio reported strong second quarter results, highlighting advancements in its gamma-delta T cell engager platform and promising clinical data for its DeltEx DRI in glioblastoma patients. The median overall survival for treated patients exceeded 19.5 months, with no significant toxicities observed. The company aims to continue its progress with upcoming preclinical data and regulatory discussions.

Read more →
INAB
Jul 9, 2026
INABPhases

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

IN8bio announced the publication of clinical results demonstrating that its DeltEx DRI therapy significantly improves progression-free survival in newly diagnosed glioblastoma patients. The Phase 1 trial showed a median progression-free survival of 16.1 months for repeat-dose patients, more than double the standard of care. The therapy was well tolerated with no dose-limiting toxicities reported, highlighting its potential as a new treatment option for this aggressive cancer.

Read more →
INAB
Jun 3, 2026
INABGeneral

IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies

IN8bio, a clinical-stage biopharmaceutical company, has announced the publication of a review article in Nature Communications, focusing on advancements in gamma-delta T cell engineering and combination therapies for cancer. The publication, authored by leading oncologists, outlines innovative strategies that could enhance anti-tumor efficacy, especially in solid tumors. In particular, the unique properties of gamma-delta T cells and their potential to improve immunotherapy approaches are underscored.

Read more →
INAB
Jun 1, 2026
INABPhases
▼ -7.5%on this news· ran to -18% by day 3shared move

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

IN8bio presented updated clinical data for its DeltEx DRI at the ASCO 2026 conference, showing a median overall survival exceeding 19.5 months and a median progression-free survival of 13.0 months among patients with newly diagnosed glioblastoma. This data indicates a significant advancement over the standard-of-care, which has not changed in over 20 years. The therapy was well tolerated with no notable adverse effects, suggesting a positive outlook for patients facing this aggressive cancer. These findings underscore the potential of gamma-delta T cell therapy in transforming glioblastoma treatment outcomes.

Read more →
INAB
May 14, 2026
INABPhases

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

IN8bio has presented new translational data highlighting the effectiveness of its DeltEx Drug Resistant Immunotherapy (DRI) in glioblastoma at major scientific forums. The findings suggest that repeated dosing of genetically modified gamma-delta T cells can preserve immune function and improve survival outcomes in patients. Data indicates a significant increase in intratumoral CD8+ T cell density, alongside reduced immune exhaustion markers, supporting the therapy's potential in reshaping the tumor microenvironment. The research lays the groundwork for future biomarker discovery and treatment optimization.

Read more →
INAB
May 8, 2026
INABGeneral

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

IN8bio reported its financial results for Q1 2026, highlighting advancements in its gamma-delta T cell therapies. The company has shown promising data for glioblastoma treatments and plans to engage with the FDA regarding regulatory pathways. Upcoming milestones include presentations at major conferences and further updates at their R&D Day in May.

Read more →
INAB
May 6, 2026
INABConferences/Events

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

IN8bio, a clinical-stage biopharmaceutical company, is set to present new clinical data and showcase its gamma-delta T cell programs at several upcoming medical conferences. Notably, they will hold an R&D Day on May 21, 2026, where they will highlight their novel T cell engager platform and its applications for cancer therapy. Key presentations will also occur at the ASCO Annual Meeting, focusing on the clinical progress of their gamma-delta T cell therapies for glioblastoma and other indications.

Read more →
INAB
Mar 13, 2026
INABGeneral

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

IN8bio reported its financial results for Q4 and full-year 2025, highlighting advancements in its gamma-delta T cell therapy programs, particularly for glioblastoma. The company announced a $40.2 million private placement to strengthen its financial position. Updated clinical data showed improved survival outcomes for patients treated with their therapies, indicating progress despite the aggressive nature of the disease.

Read more →
INAB
Feb 24, 2026
INABConferences/Events

IN8bio to Present at TD Cowen 46th Annual Health Care Conference

IN8bio, a clinical-stage biopharmaceutical company, will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO William Ho will discuss the company's recent achievements and upcoming milestones. The conference will also feature one-on-one investor meetings and will take place in Boston from March 2-4, 2026.

Read more →
INAB
Feb 9, 2026
INABGeneral

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

IN8bio has promoted Kate Rochlin, Ph.D., to President and Chief Operating Officer. Dr. Rochlin, who has been with the company since 2020, will oversee operations as IN8bio advances its clinical pipeline. She has played a key role in developing the company's T cell engager platform and has extensive experience in biotechnology. Her promotion is expected to strengthen the organization further.

Read more →
INAB
Feb 3, 2026
INABConferences/Events

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

IN8bio, Inc. announced its participation in two upcoming conferences in February 2026. CEO William Ho will present at the Noble Emerging Growth Virtual Equity Conference and the IO360° Conference, where he will discuss the company's unique DeltEx Drug Resistant Immunotherapy approach and results from a Phase 1/2 study in glioblastoma. Additional details will be available on their website.

Read more →

About IN8bio, Inc.

New York, NY 20 employees in8bio.com
HeadquartersEMPIRE STATE BUILDING, NEW YORK, NY, 10118
BIOPHARMAWATCH ELITE
Trade the next INAB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime